资讯
Bayer seeks Japanese marketing authorization for low-dose contrast agent, gadoquatrane for contrast-enhanced MRI of all body regions and CNS: Berlin Tuesday, June 3, 2025, 13:00 H ...
PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid ...
Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen 9747 AG, The Netherlands ...
Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors: Results on safety, pharmacokinetics, and anti-tumor activity. Pertuzumab plus ...
Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...
Vancomycin 265/309 (85.8%) 76/265 (25.3%) 198/309 (64.1%) † Clinical cure is resolution of diarrhea following the recommended dose of drug (fidaxomicin: 200 mg twice a day; vancomycin: 125 mg ...
18 天
Clinical Trials Arena on MSNPasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapyPasithea Therapeutics has announced the start of a Phase I/Ib open-label trial of macrocyclic mitogen-activated protein kinase (MEK) inhibitor, PAS-004, for treating adults with neurofibromatosis type ...
PeptiDream’s macrocyclic peptides can either act as medicines in their own right or can serve as targeting mechanisms for another therapeutic payload. In this case, the partners will work on ...
A recent study presents macrocyclic tau-mimicking peptides that structurally and functionally resemble these disease-associated folds, providing new tools for studying tau aggregation and ...
Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in what ...
Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified macrocyclic compounds acting as GTPase KRAS (G12D mutant) and/or (G13D mutant) inhibitors reported to be useful for ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果